NasdaqCM:BIOL

Stock Analysis Report

Executive Summary

BIOLASE, Inc., a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the worldwide.

Snowflake

Fundamentals

Imperfect balance sheet with concerning outlook.

Risks

  • BIOLASE has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has BIOLASE's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

8.1%

NasdaqCM:BIOL

-1.2%

US Medical Equipment

1.2%

US Market


1 Year Return

-48.6%

NasdaqCM:BIOL

8.7%

US Medical Equipment

1.7%

US Market

BIOL underperformed the Medical Equipment industry which returned 8.7% over the past year.

BIOL underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

BIOLIndustryMarket
7 Day8.1%-1.2%1.2%
30 Day-15.1%1.4%4.9%
90 Day-33.1%4.8%3.7%
1 Year-48.6%-48.6%9.6%8.7%3.9%1.7%
3 Year-88.4%-88.4%70.8%65.5%47.2%37.7%
5 Year-92.0%-92.0%130.4%104.1%60.0%42.4%

Price Volatility Vs. Market

How volatile is BIOLASE's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BIOLASE undervalued based on future cash flows and its price relative to the stock market?

6.17x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for BIOLASE to establish if it is available at moderate discount.

Unable to calculate intrinsic value for BIOLASE to establish if it is available at substantial discount.


Price Based on Earnings

BIOLASE is loss making, we can't compare its value to the US Medical Equipment industry average.

BIOLASE is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for BIOLASE, we can't assess if its growth is good value.


Price Based on Value of Assets

BIOLASE is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is BIOLASE expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

49.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

BIOLASE's revenue is expected to grow by 7.4% yearly, however this is not considered high growth (20% yearly).

BIOLASE is not considered high growth as it is expected to be loss making for the next 1-3 years.

BIOLASE's revenue growth is expected to exceed the United States of America market average.

Unable to compare BIOLASE's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare BIOLASE's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if BIOLASE will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has BIOLASE performed over the past 5 years?

-2.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

BIOLASE does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare BIOLASE's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare BIOLASE's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if BIOLASE has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if BIOLASE has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if BIOLASE improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is BIOLASE's financial position?


Financial Position Analysis

BIOLASE is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

BIOLASE's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

BIOLASE's level of debt (351.5%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (109.2% vs 351.5% today).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 2x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

BIOLASE has less than a year of cash runway based on current free cash flow.

BIOLASE has less than a year of cash runway if free cash flow continues to grow at historical rates of 3% each year.


Next Steps

Dividend

What is BIOLASE's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate BIOLASE's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate BIOLASE's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as BIOLASE has not reported any payouts.

Unable to verify if BIOLASE's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as BIOLASE has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of BIOLASE's salary, the management and board of directors tenure and is there insider trading?

3.2yrs

Average management tenure


CEO

Todd Norbe (52yo)

1.1yrs

Tenure

US$1,966,778

Compensation

Mr. Todd A. Norbe is President and Chief Executive Officer at BIOLASE, Inc. since August 8, 2018. He served as President of Dental/Medical Solutions at Sybron Dental Specialties, Inc. Mr. Norbe serves as t ...


CEO Compensation Analysis

Todd's remuneration is higher than average for companies of similar size in United States of America.

Insufficient data for Todd to compare compensation growth.


Management Age and Tenure

3.2yrs

Average Tenure

54.5yo

Average Age

The tenure for the BIOLASE management team is about average.


Board Age and Tenure

1.3yrs

Average Tenure

61yo

Average Age

The average tenure for the BIOLASE board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$1,500,00027 Jun 19
Oracle Investment Management, Inc.
EntityCompany
Shares1,000,000
Max PriceUS$1.50
BuyUS$5,35015 Dec 18
Garrett Sato
EntityIndividual
Role
Member of the Board of Directors
Director
Shares5,000
Max PriceUS$1.07
BuyUS$15,46915 Dec 18
Todd Norbe
EntityIndividual
Role
Chief Executive Officer
President
Shares15,000
Max PriceUS$1.04
BuyUS$1,18006 Dec 18
John Beaver
EntityIndividual
Role
Chief Financial Officer
Executive VP & CFO
Shares1,000
Max PriceUS$1.18
BuyUS$6,10030 Nov 18
Garrett Sato
EntityIndividual
Role
Member of the Board of Directors
Director
Shares5,000
Max PriceUS$1.22
BuyUS$13,60021 Nov 18
Jonathan Lord
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares10,000
Max PriceUS$1.36

Ownership Breakdown


Management Team

  • Michael Carroll (47yo)

    Corporate Secretary

    • Tenure: 0yrs
  • John Beaver (58yo)

    Executive VP & CFO

    • Tenure: 1.9yrs
    • Compensation: US$628.87k
  • Todd Norbe (52yo)

    President

    • Tenure: 1.1yrs
    • Compensation: US$1.97m
  • Bill Brown (71yo)

    Vice President of Business Development

    • Tenure: 6.2yrs
    • Compensation: US$284.10k
  • Matt Wilson

    Vice President of Human Resources

    • Tenure: 3.3yrs
  • Rick Whipp (67yo)

    Vice President of Operations

    • Tenure: 7.9yrs
  • Dan Merkin (46yo)

    National Sales Director

    • Tenure: 0yrs
    • Compensation: US$243.55k
  • Sam Low

    Chief Dental Officer and VP of Dental & Clinical Affairs

    • Tenure: 2.9yrs
    • Compensation: US$50.44k
  • Brendan O’Connell (42yo)

    Vice President of Finance and Corporate Controller

    • Tenure: 4.7yrs
  • Holger Arens (57yo)

    VP & MD of Europe

    • Tenure: 3yrs

Board Members

  • Richard Lanman (64yo)

    Director

    • Tenure: 1.9yrs
    • Compensation: US$117.50k
  • Jack Lord (64yo)

    Chairman of the Board

    • Tenure: 2yrs
    • Compensation: US$249.60k
  • Todd Norbe (52yo)

    President

    • Tenure: 1.1yrs
    • Compensation: US$1.97m
  • Jess Roper (54yo)

    Director

    • Tenure: 1.3yrs
    • Compensation: US$104.17k
  • Garrett Sato (58yo)

    Director

    • Tenure: 1.4yrs
    • Compensation: US$129.61k
  • Elaine Wagner (65yo)

    Board of Directors

    • Tenure: 0.9yrs
    • Compensation: US$66.56k

Company Information

BIOLASE, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BIOLASE, Inc.
  • Ticker: BIOL
  • Exchange: NasdaqCM
  • Founded: 1984
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$23.448m
  • Shares outstanding: 21.91m
  • Website: https://www.biolase.com

Number of Employees


Location

  • BIOLASE, Inc.
  • 4 Cromwell
  • Irvine
  • California
  • 92618
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BIOLNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMar 1992
BTH1DB (Deutsche Boerse AG)YesCommon StockDEEURMar 1992

Biography

BIOLASE, Inc., a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the worldwide. The company offers W ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/14 23:32
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.